Trade Bioventus Inc. - BVS CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.10 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Bioventus Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 2.95 |
| Open* | 2.89 |
| 1-Year Change* | -58.6% |
| Day's Range* | 2.89 - 2.96 |
| 52 wk Range | 0.80-8.56 |
| Average Volume (10 days) | 325.09K |
| Average Volume (3 months) | 9.18M |
| Market Cap | 260.10M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 78.58M |
| Revenue | 510.62M |
| EPS | -3.61 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | Nov 6, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Oct 3, 2023 | 2.95 | -0.14 | -4.53% | 3.09 | 3.14 | 2.91 |
| Oct 2, 2023 | 3.15 | -0.09 | -2.78% | 3.24 | 3.32 | 3.08 |
| Sep 29, 2023 | 3.28 | 0.29 | 9.70% | 2.99 | 3.30 | 2.99 |
| Sep 28, 2023 | 2.99 | 0.04 | 1.36% | 2.95 | 3.07 | 2.90 |
| Sep 27, 2023 | 2.99 | 0.05 | 1.70% | 2.94 | 3.01 | 2.88 |
| Sep 26, 2023 | 2.92 | 0.07 | 2.46% | 2.85 | 3.00 | 2.82 |
| Sep 25, 2023 | 2.92 | 0.02 | 0.69% | 2.90 | 2.96 | 2.80 |
| Sep 22, 2023 | 2.91 | 0.05 | 1.75% | 2.86 | 2.94 | 2.85 |
| Sep 21, 2023 | 2.88 | -0.14 | -4.64% | 3.02 | 3.03 | 2.85 |
| Sep 20, 2023 | 3.05 | -0.04 | -1.29% | 3.09 | 3.14 | 3.01 |
| Sep 19, 2023 | 3.07 | 0.06 | 1.99% | 3.01 | 3.12 | 3.01 |
| Sep 18, 2023 | 3.02 | 0.05 | 1.68% | 2.97 | 3.06 | 2.96 |
| Sep 15, 2023 | 3.01 | 0.01 | 0.33% | 3.00 | 3.04 | 2.95 |
| Sep 14, 2023 | 3.04 | -0.03 | -0.98% | 3.07 | 3.13 | 3.01 |
| Sep 13, 2023 | 3.08 | -0.01 | -0.32% | 3.09 | 3.14 | 3.03 |
| Sep 12, 2023 | 3.10 | 0.01 | 0.32% | 3.09 | 3.20 | 3.09 |
| Sep 11, 2023 | 3.16 | 0.06 | 1.94% | 3.10 | 3.23 | 3.09 |
| Sep 8, 2023 | 3.11 | -0.08 | -2.51% | 3.19 | 3.26 | 3.04 |
| Sep 7, 2023 | 3.29 | -0.06 | -1.79% | 3.35 | 3.37 | 3.19 |
| Sep 6, 2023 | 3.42 | -0.04 | -1.16% | 3.46 | 3.52 | 3.35 |
Bioventus Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, November 6, 2023 | ||
| Time (UTC) 13:30 | Country US
| Event Q3 2023 Bioventus Inc Earnings Release Q3 2023 Bioventus Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 512.117 | 430.898 | 321.161 | 340.141 | 319.177 |
| Revenue | 512.117 | 430.898 | 321.161 | 340.141 | 319.177 |
| Cost of Revenue, Total | 181.037 | 128.192 | 87.642 | 90.935 | 84.168 |
| Gross Profit | 331.08 | 302.706 | 233.519 | 249.206 | 235.009 |
| Total Operating Expense | 763.165 | 420.999 | 295.801 | 311.933 | 293.673 |
| Selling/General/Admin. Expenses, Total | 332.606 | 254.253 | 187.469 | 198.206 | 191.672 |
| Research & Development | 25.941 | 19.039 | 11.202 | 11.055 | 8.095 |
| Depreciation / Amortization | 21.153 | 8.363 | 7.439 | 7.908 | 8.615 |
| Unusual Expense (Income) | 195.976 | 10.323 | 2.049 | 3.829 | 1.862 |
| Other Operating Expenses, Total | 6.452 | 0.829 | 0 | 0 | -0.739 |
| Operating Income | -251.048 | 9.899 | 25.36 | 28.208 | 25.504 |
| Interest Income (Expense), Net Non-Operating | -24.692 | 1.77 | -9.091 | -17.891 | -18.66 |
| Other, Net | 11.841 | -4.049 | -0.355 | -0.628 | -0.737 |
| Net Income Before Taxes | -263.899 | 7.62 | 15.914 | 9.689 | 6.107 |
| Net Income After Taxes | -213.391 | 9.586 | 14.722 | 8.113 | 4.443 |
| Minority Interest | 54.687 | 9.789 | 1.689 | 0.553 | 0 |
| Net Income Before Extra. Items | -158.704 | 19.375 | 16.411 | 8.666 | 4.443 |
| Total Extraordinary Items | 0 | 0 | -1.815 | -16.65 | |
| Net Income | -158.704 | 19.375 | 16.411 | 6.851 | -12.207 |
| Total Adjustments to Net Income | -12.028 | -7.51 | -5.781 | ||
| Income Available to Common Excl. Extra. Items | -158.704 | 19.375 | 4.383 | 1.156 | -1.338 |
| Income Available to Common Incl. Extra. Items | -158.704 | 19.375 | 4.383 | -0.659 | -17.988 |
| Diluted Net Income | -158.704 | 19.375 | 4.383 | -0.659 | -17.988 |
| Diluted Weighted Average Shares | 61.3891 | 45.4725 | 55.6253 | 55.6253 | 55.6253 |
| Diluted EPS Excluding Extraordinary Items | -2.58521 | 0.42608 | 0.0788 | 0.02078 | -0.02405 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Diluted Normalized EPS | -0.0549 | 1.03994 | 0.20655 | 0.16588 | 0.0261 |
| Jul 2023 | Apr 2023 | Dec 2022 | Oct 2022 | Jul 2022 | |
|---|---|---|---|---|---|
| Total revenue | 137.069 | 119.059 | 125.834 | 128.662 | 140.331 |
| Revenue | 137.069 | 119.059 | 125.834 | 128.662 | 140.331 |
| Cost of Revenue, Total | 47.946 | 45.14 | 51.645 | 44.127 | 43.677 |
| Gross Profit | 89.123 | 73.919 | 74.189 | 84.535 | 96.654 |
| Total Operating Expense | 130.319 | 211.117 | 151.269 | 329.517 | 143.639 |
| Selling/General/Admin. Expenses, Total | 74.844 | 80.858 | 77.668 | 79.194 | 89.62 |
| Research & Development | 3.398 | 3.771 | 6.807 | 5.84 | 6.366 |
| Depreciation / Amortization | 2.294 | 2.129 | 7.761 | 7.442 | 2.696 |
| Operating Income | 6.75 | -92.058 | -25.435 | -200.855 | -3.308 |
| Interest Income (Expense), Net Non-Operating | -10.587 | -9.694 | -14.873 | -9.894 | -2.579 |
| Other, Net | -0.513 | 1.588 | -9.406 | 23.272 | -0.603 |
| Net Income Before Taxes | -4.35 | -100.164 | -49.714 | -187.477 | -6.49 |
| Net Income After Taxes | -4.731 | -100.018 | -44.873 | -145.698 | -7.734 |
| Minority Interest | 1.05 | 20.36 | 12.943 | 37.453 | 0.762 |
| Net Income Before Extra. Items | -3.681 | -79.658 | -31.93 | -108.245 | -6.972 |
| Net Income | -3.681 | -139.15 | -31.93 | -108.245 | -7.252 |
| Income Available to Common Excl. Extra. Items | -3.681 | -79.658 | -31.93 | -108.245 | -6.972 |
| Income Available to Common Incl. Extra. Items | -3.681 | -139.15 | -31.93 | -108.245 | -7.252 |
| Diluted Net Income | -3.681 | -139.15 | -31.93 | -108.245 | -7.252 |
| Diluted Weighted Average Shares | 62.5513 | 62.1247 | 61.9296 | 61.6743 | 61.4753 |
| Diluted EPS Excluding Extraordinary Items | -0.05885 | -1.28223 | -0.51559 | -1.75511 | -0.11341 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | 0.04562 | -0.34997 | -0.29682 | 0.33166 | -0.02298 |
| Unusual Expense (Income) | 1.597 | 78.932 | 4.62 | 189.772 | 1.007 |
| Other Operating Expenses, Total | 0.24 | 0.287 | 2.768 | 3.142 | 0.273 |
| Total Extraordinary Items | 0 | -59.492 | -0.28 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 272.575 | 263.103 | 211.794 | 183.033 | 148.354 |
| Cash and Short Term Investments | 31.814 | 43.933 | 86.839 | 64.52 | 42.774 |
| Cash & Equivalents | 31.814 | 43.933 | 86.839 | 64.52 | 42.774 |
| Total Receivables, Net | 136.912 | 125.045 | 88.364 | 85.389 | 73.041 |
| Accounts Receivable - Trade, Net | 136.912 | 125.045 | 88.364 | 85.389 | 73.041 |
| Total Inventory | 85.408 | 61.688 | 29.12 | 27.326 | 27.396 |
| Prepaid Expenses | 18.418 | 27.157 | 7.471 | 5.798 | 4.713 |
| Other Current Assets, Total | 0.023 | 5.28 | 0.43 | ||
| Total Assets | 1372.65 | 1225.86 | 494.466 | 472.407 | 442.723 |
| Property/Plant/Equipment, Total - Net | 44.955 | 40.171 | 21.84 | 19.756 | 4.759 |
| Property/Plant/Equipment, Total - Gross | 75.827 | 52.818 | 42.161 | 37.998 | 23.515 |
| Accumulated Depreciation, Total | -30.872 | -23.1 | -20.321 | -18.242 | -18.756 |
| Goodwill, Net | 13.759 | 147.623 | 49.8 | 49.8 | 49.8 |
| Intangibles, Net | 1038.72 | 695.193 | 191.65 | 216.51 | 237.029 |
| Long Term Investments | 2.636 | 29.291 | 19.382 | 3.308 | 2.781 |
| Total Current Liabilities | 304.017 | 180.859 | 122.589 | 89.015 | 65.428 |
| Accounts Payable | 37.549 | 16.915 | 4.422 | 6.44 | 8.207 |
| Accrued Expenses | 113.11 | 137.713 | 98.767 | 67.633 | 48.952 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 33.056 | 18.038 | 15 | 10.041 | 5.25 |
| Other Current Liabilities, Total | 120.302 | 8.193 | 4.4 | 4.901 | 3.019 |
| Total Liabilities | 1056.07 | 766.938 | 352.225 | 329.425 | 297.456 |
| Total Long Term Debt | 385.01 | 339.644 | 173.378 | 187.978 | 189.578 |
| Long Term Debt | 385.01 | 339.644 | 173.378 | 187.965 | 189.578 |
| Deferred Income Tax | 154.001 | 133.518 | 3.362 | 3.874 | 3.955 |
| Minority Interest | 23.751 | 74.865 | 1.919 | 2.635 | 0 |
| Other Liabilities, Total | 189.289 | 38.052 | 50.977 | 45.923 | 38.495 |
| Total Equity | 316.581 | 458.924 | 142.241 | 142.982 | 145.267 |
| Redeemable Preferred Stock | 210.576 | 204.443 | 198.488 | ||
| Preferred Stock - Non Redeemable, Net | -42.576 | -36.443 | -30.488 | ||
| Common Stock | 0.078 | 0.075 | 113.373 | 113.373 | 113.373 |
| Retained Earnings (Accumulated Deficit) | -165.306 | -6.602 | -140.739 | -137.926 | -136.041 |
| Other Equity, Total | -0.11 | 0.179 | 1.607 | -0.465 | -0.065 |
| Total Liabilities & Shareholders’ Equity | 1372.65 | 1225.86 | 494.466 | 472.407 | 442.723 |
| Total Common Shares Outstanding | 77.8497 | 75.3352 | 55.6253 | 55.6253 | 55.6253 |
| Capital Lease Obligations | 0.013 | ||||
| Other Long Term Assets, Total | 0 | 50.481 | |||
| Additional Paid-In Capital | 481.919 | 465.272 |
| Apr 2023 | Dec 2022 | Oct 2022 | Jul 2022 | Apr 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 308.664 | 272.575 | 271.082 | 277.157 | 245.395 |
| Cash and Short Term Investments | 47.102 | 31.814 | 34.359 | 41.001 | 27.374 |
| Cash & Equivalents | 47.102 | 31.814 | 34.359 | 41.001 | 27.374 |
| Total Receivables, Net | 118.544 | 136.912 | 132.185 | 143.018 | 119.288 |
| Accounts Receivable - Trade, Net | 118.544 | 136.912 | 132.185 | 143.018 | 119.288 |
| Total Inventory | 87.953 | 85.408 | 76.952 | 69.078 | 64.691 |
| Prepaid Expenses | 17.192 | 18.418 | 27.563 | 24.06 | 28.762 |
| Other Current Assets, Total | 37.873 | 0.023 | 0.023 | 0 | 5.28 |
| Total Assets | 887.404 | 1372.65 | 1398.02 | 1208.78 | 1197.14 |
| Property/Plant/Equipment, Total - Net | 52.619 | 44.955 | 42.947 | 43.454 | 43.594 |
| Goodwill, Net | 7.462 | 13.759 | 15.359 | 143.156 | 147.968 |
| Intangibles, Net | 516.039 | 1038.72 | 1055.6 | 666.523 | 681.369 |
| Long Term Investments | 2.62 | 2.636 | 13.033 | 78.486 | 28.811 |
| Other Long Term Assets, Total | 0 | 0 | 0 | 50 | |
| Total Current Liabilities | 196.063 | 304.017 | 288.373 | 198.873 | 171.522 |
| Accounts Payable | 32.828 | 37.549 | 19.075 | 25.735 | 22.5 |
| Accrued Expenses | 115.127 | 113.11 | 118.025 | 123.833 | 112.94 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 41.32 | 33.056 | 31.302 | 22.547 | 20.292 |
| Other Current Liabilities, Total | 6.788 | 120.302 | 119.971 | 26.758 | 15.79 |
| Total Liabilities | 698.893 | 1056.07 | 1054.62 | 760.795 | 747.361 |
| Total Long Term Debt | 404.265 | 385.01 | 393.102 | 351.433 | 348.039 |
| Long Term Debt | 404.265 | 385.01 | 393.102 | 351.433 | 348.039 |
| Deferred Income Tax | 0.351 | 154.001 | 159.3 | 98.892 | 116.02 |
| Minority Interest | 51.851 | 23.751 | 35.749 | 72.209 | 72.142 |
| Other Liabilities, Total | 46.363 | 189.289 | 178.101 | 39.388 | 39.638 |
| Total Equity | 188.511 | 316.581 | 343.397 | 447.981 | 449.776 |
| Common Stock | 0.079 | 0.078 | 0.08 | 0.08 | 0.078 |
| Additional Paid-In Capital | 492.475 | 481.919 | 478.033 | 473.796 | 467.94 |
| Retained Earnings (Accumulated Deficit) | -304.456 | -165.306 | -133.376 | -25.131 | -17.879 |
| Other Equity, Total | 0.413 | -0.11 | -1.34 | -0.764 | -0.363 |
| Total Liabilities & Shareholders’ Equity | 887.404 | 1372.65 | 1398.02 | 1208.78 | 1197.14 |
| Total Common Shares Outstanding | 78.2946 | 77.8497 | 77.5646 | 77.4432 | 77.144 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -213.391 | 9.586 | 14.722 | 6.298 | -12.207 |
| Cash From Operating Activities | -13.537 | 22.991 | 71.799 | 40.713 | 45.187 |
| Cash From Operating Activities | 66.803 | 34.875 | 28.643 | 30.316 | 29.238 |
| Deferred Taxes | -52.792 | -9.756 | -0.511 | -0.348 | -0.079 |
| Non-Cash Items | 200.375 | 1.563 | 13.637 | 18.019 | 25.383 |
| Cash Taxes Paid | 1.518 | 7.456 | 1.541 | 1.577 | 1.944 |
| Cash Interest Paid | 18.043 | 5.837 | 7.486 | 15.45 | 17.273 |
| Changes in Working Capital | -14.532 | -13.277 | 15.308 | -13.572 | 2.852 |
| Cash From Investing Activities | -116.436 | -283.76 | -20.5 | -7.912 | -6.101 |
| Capital Expenditures | -10.042 | -7.37 | -4.093 | -2.342 | -2.561 |
| Other Investing Cash Flow Items, Total | -106.394 | -276.39 | -16.407 | -5.57 | -3.54 |
| Cash From Financing Activities | 62.076 | 273.371 | -29.569 | -10.951 | -13.256 |
| Financing Cash Flow Items | -3.367 | -2.242 | -19.569 | -9.504 | -7.846 |
| Issuance (Retirement) of Debt, Net | 59.621 | 166.203 | -10 | -1.447 | -5.41 |
| Foreign Exchange Effects | 0.521 | -0.228 | 0.589 | -0.104 | -0.16 |
| Net Change in Cash | -67.376 | 12.374 | 22.319 | 21.746 | 25.67 |
| Issuance (Retirement) of Stock, Net | 5.822 | 109.41 |
| Apr 2023 | Dec 2022 | Oct 2022 | Jul 2022 | Apr 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -174.447 | -213.391 | -168.518 | -22.82 | -14.806 |
| Cash From Operating Activities | 2.49 | -13.537 | -18.781 | -18.08 | -21.019 |
| Cash From Operating Activities | 16.473 | 66.803 | 43.643 | 24.863 | 12.479 |
| Deferred Taxes | -2.664 | -52.792 | -47.154 | -27.698 | -17.018 |
| Non-Cash Items | 155.058 | 200.375 | 183.873 | 9.784 | 2.633 |
| Changes in Working Capital | 8.07 | -14.532 | -30.625 | -2.209 | -4.307 |
| Cash From Investing Activities | -15.066 | -116.436 | -113.033 | -56.699 | -4.674 |
| Capital Expenditures | -3.56 | -10.042 | -6.639 | -4.99 | -2.96 |
| Other Investing Cash Flow Items, Total | -11.506 | -106.394 | -106.394 | -51.709 | -1.714 |
| Cash From Financing Activities | 27.38 | 62.076 | 67.514 | 16.86 | 9.205 |
| Financing Cash Flow Items | -1.704 | -3.367 | -3.356 | -3.378 | -3.366 |
| Issuance (Retirement) of Stock, Net | 0.084 | 5.822 | 4.739 | 4.257 | 2.08 |
| Issuance (Retirement) of Debt, Net | 29 | 59.621 | 66.131 | 15.981 | 10.491 |
| Foreign Exchange Effects | 0.461 | 0.521 | -0.531 | -0.293 | -0.071 |
| Net Change in Cash | 15.265 | -67.376 | -64.831 | -58.212 | -16.559 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Bioventus Inc. Company profile
About Bioventus Inc
Bioventus Inc is a global medical device company. The Company is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Bioventus Inc revenues increased 34% to $430.9M. Net income applicable to common stockholders increased from $4.4M to $19.4M. Revenues reflect U.S. segment increase of 32% to $387.6M, International segment increase of 58% to $43.3M. Net income benefited from Stock-based Compensation in SGA decrease from $10.1M (expense) to $4.5M (income), Foreign Exchange Gain/Loss increase of 13% to $132K (income).
| Industry: | Medical Equipment |
4721 Emperor Boulevard, Suite 100
DURHAM
NORTH CAROLINA 27703
US
Income Statement
- Annual
- Quarterly
News
How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com